Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | company profile
InterMune Inc - Premium Company Profile (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 24/12/2007
- Report Title: InterMune Inc - Premium Company Profile
- Table of Contents: View Table of Contents
- Report Type: Company Profile
- Country: Global
- Number of Pages: 50
Introduction
InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The company markets Actimmune (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. The company acquired core patents for pirfenidone from Marnac and KDL in November 2007.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
InterMune has a late-stage and preclinical development pipeline in the areas of pulmonology and hepatology. In pulmonology, the company is developing two therapies for the treatment of idiopathic pulmonary fibrosis (IPF): interferon gamma-1b and pirfenidone and in hepatology, it is expanding options for patients suffering from HCV infections
Historically, the company derived majority of its revenues during 2002-2006 from product sales of Actimmune, Infergen, Amphotec and Oritavancin. The company's total revenues decreased at a CAGR of -5% during 2002-2006, from $112 million to $91 million, representing an absolute decline of -$21 million for the same period.
InterMune's biggest contributor to sales growth out to 2010 will be revenues from Pirfenidone sales. Revenues from Pirfenidone are expected to contribute $111 million in 2010, representing an absolute growth of +$111 million for the period 2006-2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization
Scope
Highlights
Reasons to Purchase
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
